CRISPR Therapeutics (CRSP) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart

CRISPR Therapeutics Revenue Highlights

Latest Revenue (Y)

$3.51M

Latest Revenue (Q)

$1.46M

Main Segment (Y)

Grant

CRISPR Therapeutics Revenue by Period

CRISPR Therapeutics Revenue by Year

Date	Revenue	Change
2025-12-31	$3.51M	-89.97%
2024-12-31	$35.00M	-90.54%
2023-12-31	$370.00M	84762.39%
2022-12-31	$436.00K	-99.95%
2021-12-31	$913.08M	126893.18%
2020-12-31	$719.00K	-99.75%
2019-12-31	$289.59M	9169.85%
2018-12-31	$3.12M	-92.38%
2017-12-31	$41.00M	693.90%
2016-12-31	$5.16M	1990.69%
2015-12-31	$247.00K	100.00%
2014-12-31	-	-

CRISPR Therapeutics generated $3.51M in revenue during NA 2025, up -89.97% compared to the previous quarter, and up 488.18% compared to the same period a year ago.

CRISPR Therapeutics Revenue by Quarter

Date	Revenue	Change
2026-03-31	$1.46M	68.75%
2025-12-31	$864.00K	-2.81%
2025-09-30	$889.00K	-0.34%
2025-06-30	$892.00K	3.12%
2025-03-31	$865.00K	-97.53%
2024-12-31	$35.00M	5713.95%
2024-09-30	$602.00K	16.44%
2024-06-30	$517.00K	2.58%
2024-03-31	$504.00K	-99.75%
2023-12-31	$200.00M	100.00%
2023-09-30	-	-100.00%
2023-06-30	$70.00M	-30.00%
2023-03-31	$100.00M	1666566.67%
2022-12-31	$6.00K	-93.62%
2022-09-30	$94.00K	-40.51%
2022-06-30	$158.00K	-11.24%
2022-03-31	$178.00K	-98.62%
2021-12-31	$12.90M	3820.67%
2021-09-30	$329.00K	-99.96%
2021-06-30	$900.20M	445544.55%
2021-03-31	$202.00K	-45.41%
2020-12-31	$370.00K	150.00%
2020-09-30	$148.00K	236.36%
2020-06-30	$44.00K	-71.97%
2020-03-31	$157.00K	-99.80%
2019-12-31	$77.02M	-63.66%
2019-09-30	$211.93M	66544.03%
2019-06-30	$318.00K	-3.05%
2019-03-31	$328.00K	185.22%
2018-12-31	$115.00K	-79.57%
2018-09-30	$563.00K	-48.25%
2018-06-30	$1.09M	-19.88%
2018-03-31	$1.36M	-95.80%
2017-12-31	$32.33M	1254.21%
2017-09-30	$2.39M	-33.36%
2017-06-30	$3.58M	32.52%
2017-03-31	$2.70M	15.32%
2016-12-31	$2.34M	51.32%
2016-09-30	$1.55M	94.84%
2016-06-30	$795.00K	67.02%
2016-03-31	$476.00K	92.71%
2015-12-31	$247.00K	100.00%
2015-09-30	-	-

CRISPR Therapeutics generated $1.46M in revenue during Q1 2026, up 68.75% compared to the previous quarter, and up 4.17% compared to the same period a year ago.

CRISPR Therapeutics Revenue Breakdown

CRISPR Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Grant	$3.51M	$2.31M	$1.21M	$762.00K	-
Collaboration Revenue	-	$35.00M	$370.00M	$436.00K	-
Myotonic Dystrophy Type One R And D Services	-	-	-	-	$1.10M
Specified Target Option Material Right	-	-	-	-	$11.80M
Myotonic Dystrophy Type One License	-	-	-	-	$51.30M
Collaborative Arrangement Material Rights Fourth Exclusive License	-	-	-	-	$6.70M
Collaborative Arrangement Material Rights	-	-	-	-	$46.70M
Duchenne Muscular Dystrophy License	-	-	-	-	$151.10M
Exclusive License	-	-	-	-	$900.00M

CRISPR Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Grant (100.00%).

Quarterly Revenue by Product

Product/Service	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
Collaboration Revenue	$1.00M	-	-	$200.00M	$70.00M	$100.00M	$6.00K	$94.00K	$158.00K	$178.00K	$12.35M	-	-	-	-	-	-	-	-	-
Grant	$458.00K	$864.00K	$889.00K	$892.00K	$865.00K	$691.00K	$602.00K	$517.00K	$504.00K	-	-	-	-	-	$762.00K	$551.00K	-	-	-	-
Myotonic Dystrophy Type One R And D Services	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.10M	$1.10M	$1.10M
Collaborative Arrangement Material Rights	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$46.70M	$46.70M	$46.70M
Myotonic Dystrophy Type One License	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$51.30M	$51.30M	$51.30M
Duchenne Muscular Dystrophy License	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$151.10M	$151.10M	$151.10M
Specified Target Option Material Right	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$11.80M	$11.80M	$11.80M

CRISPR Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 26: Collaboration Revenue (68.59%), and Grant (31.41%).

CRISPR Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
PTCT	PTC Therapeutics	$1.73B	$272.55M
ARWR	Arrowhead Pharmaceuticals	$829.45M	$73.74M
TGTX	TG Therapeutics	$616.29M	$204.92M
KRYS	Krystal Biotech	$389.13M	$116.36M
CYTK	Cytokinetics	$88.04M	$19.36M
CRSP	CRISPR Therapeutics	$3.51M	$1.46M
AKRO	Akero Therapeutics	-	-
PCVX	Vaxcyte	-	-
NUVL	Nuvalent	-	-
MTSR	Metsera	-	-
ACLX	Arcellx	-	$7.55M

CRSP Revenue FAQ

What is CRISPR Therapeutics’s yearly revenue?

CRISPR Therapeutics's yearly revenue for 2025 was $3.51M, representing a decrease of -89.97% compared to 2024. The company's yearly revenue for 2024 was $35M, representing a decrease of -90.54% compared to 2023. CRSP's yearly revenue for 2023 was $370M, representing an increase of 84762.39% compared to 2022.

What is CRISPR Therapeutics’s quarterly revenue?

CRISPR Therapeutics's quarterly revenue for Q1 2026 was $1.46M, a 68.75% increase from the previous quarter (Q4 2025), and a 68.55% increase year-over-year (Q1 2025). The company's quarterly revenue for Q4 2025 was $864K, a -2.81% decrease from the previous quarter (Q3 2025), and a -97.53% decrease year-over-year (Q4 2024). CRSP's quarterly revenue for Q3 2025 was $889K, a -0.34% decrease from the previous quarter (Q2 2025), and a 47.67% increase year-over-year (Q3 2024).

What is CRISPR Therapeutics’s revenue growth rate?

CRISPR Therapeutics's revenue growth rate for the last 3 years (2023-2025) was -99.05%, and for the last 5 years (2021-2025) was -99.62%.

What are CRISPR Therapeutics’s revenue streams?

CRISPR Therapeutics's revenue streams in c 25 are Grant

What is CRISPR Therapeutics’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of CRISPR Therapeutics was Grant. This segment made a revenue of $3.51M, representing 100.00% of the company's total revenue.